Clinical trials: High Risk Cancer
Pancreas, Cancer
Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer
Patients with unresectable pancreatic cancer in most of cases cannot benefit from percutaneous ablation modalities, due to high risk of procedure-related complications.
- Conditions
- Pancreas, Cancer, Locally Advanced Pancreatic Cancer, Non-invasive Treatment
- Trial name
- NCT01786850
- Testing
- Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)
- Where
- Italy
- Sponsor
- University of Roma La Sapienza
Multiple Myeloma
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
- Trial name
- NCT00306735
- Testing
- Palonosetron
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eisai Inc.
Neuroblastoma, Ewing Sarcoma
Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors
To evaluate feasibility and efficacy of haploidentical stem cell transplantation in patients with high-risk solid tumors who failed after tandem high-dose chemotherapy and autologous stem cell transplantation.
- Conditions
- Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
- Trial name
- NCT01807468
- Testing
- haploidentical stem cell transplantation and NK cell therapy
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Samsung Medical Center
Central Nervous System Tumors
Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
Independently, both lenalidomide and vorinostat have shown promising activity in pediatric central nervous system (CNS) tumors. These are both agents that are not typically part of first-line studies, although both agents are of…
- Trial name
- NCT03050450
- Testing
- 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins All Children's Hospital
Esophageal Squamous Cell Carcinoma, Dysplasia
Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)
To evaluate the efficacy of endoscopic screening on esophageal cancer (EC) and determine the most cost-effective strategy of endoscopic screening in high risk population in China, 668 villages of Hua county, a high risk area of…
- Trial name
- ESECC (NCT01688908)
- Testing
- Endoscopic Screening
- Where
- China
- Volunteers
- 33,948 people, healthy volunteers welcome
- Sponsor
- Peking University
Colorectal Polyp, Colorectal Cancer Recurrent
Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy
The characteristics of the intestinal microbiota in high-risk colorectal polyp recurrence and their relationship with disease pathogenesis have not yet been fully elucidated.
- Conditions
- Colorectal Polyp, Colorectal Cancer Recurrent, Colorectal Adenoma
- Trial name
- NCT06957626
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Uterine Leiomyoma
Directed Ablation of Uterine Fibroids Using a Noninvasive Approach
The purpose of this clinical study is to assess the safety and effectiveness of the Mirabilis System for treating uterine fibroids in women who are seeking relief from fibroid-related abnormal uterine bleeding but want to avoid…
- Trial name
- DIANA (NCT03219385)
- Testing
- Mirabilis System
- Volunteers
- 180 people
- Sponsor
- Mirabilis Medica, Inc.
Chronic Lymphocytic Leukemia
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
The purpose of the study is to investigate whether the combination of obinutuzumab and ibrutinib (administered up to 840 mg per day) might be useful for the treatment of CLL or SLL that is not responding or no longer responding…
- Trial name
- NCT02611908
- Testing
- ibrutinib, obinutuzumab
- Sponsor
- Michael Choi
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
- Trial name
- DENALI (NCT05128825)
- Testing
- azenosertib
- Where
- 89 sites in United States, Australia and 7 more
- Volunteers
- 310 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Melanoma
Nivolumab Plus Radiotherapy in Advanced Melanoma
Combining nivolumab with conventional multisite high dose radiotherapy seems to be an interesting approach that could increase the antitumoral effect of nivolumab by increasing the diversity and quantity of tumoral antigen…
- Trial name
- NIRVANA (NCT02799901)
- Testing
- Nivolumab, hypofractionned radiotherapy
- Where
- 14 sites in France
- Volunteers
- 72 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Endometrial Cancer
DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer
This is a multicenter, retrospective, observational (non-interventional) study, in patients treated in a real-world setting within the Spanish dostarlimab EAP.
- Trial name
- DORA (NCT05728814)
- Testing
- Dostarlimab
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
This phase II trial compares the effect of adding a Live Biotherapeutic Product called CBM588 to pembrolizumab versus pembrolizumab alone in preventing return of disease (recurrence) after surgery for patients with renal cell…
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT07037004
- Testing
- Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- City of Hope Medical Center
Osteosarcoma
Upfront Surgical Resection for Osteosarcoma
The goal of this pilot study is to learn about patients with newly diagnosed osteosarcoma of an extremity, and whether surgically removing the tumor prior to the administration of any chemotherapy will improve functional…
- Trial name
- UFSR for OS (NCT06384404)
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Montefiore Medical Center
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of…
- Conditions
- Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL), Primary Mediastinal Large B-Cell Lymphoma-Refractory
- Trial name
- CD20/19 CAR T (NCT06703892)
- Testing
- GF-CART01
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
Relapsed Non-Hodgkin-Lymphoma
Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma
The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy in patients with relapsed/refractory aggressive and…
- Trial name
- Mz-135 (NCT02099292)
- Testing
- Rituximab and DexaBEAM
- Volunteers
- 103 people
- Sponsor
- Georg Hess, MD
Endometrial Cancer
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
This is a window study where treatment-naïve patients will receive olaparib before definitive treatment. The aim is to evaluate the DNA damage and inflammatory response after PARP inhibitor.
- Trial name
- NCT05320757
- Testing
- Olaparib
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong
Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
This phase II trial studies how well sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery work in treating patients with high-risk stage IIB-IV soft tissue sarcoma.
- Conditions
- Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
- Trial name
- NCT02050919
- Testing
- Epirubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer, Radiotherapy Side Effect
Prostate Reirradiation Toxicity Outcomes Feasibility Study
The RO-PIP trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage ultra-hypofractionated external beam radiotherapy or high dose rate brachytherapy and provide prospective data on…
- Trial name
- RO-PIP (NCT05614700)
- Testing
- Brachytherapy, Sterotactic Body Radiotherapy
- Volunteers
- 60 people
- Sponsor
- University of Leeds
Leukemia, Lymphoma
Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004898
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.